Why Is Aardvark Therapeutics Stock Sinking Monday?

Benzinga03-02

Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616331734?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/02/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-03-02 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616331734","market":"us","top_or_hot":-1,"title":"Why Is Aardvark Therapeutics Stock Sinking Monday?","media":"Benzinga","content":"<div>\n<p>Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\n...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/50960206/why-is-aardvark-therapeutics-stock-sinking-monday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Aardvark Therapeutics Stock Sinking Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Aardvark Therapeutics Stock Sinking Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 20:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/50960206/why-is-aardvark-therapeutics-stock-sinking-monday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\n...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/50960206/why-is-aardvark-therapeutics-stock-sinking-monday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/50960206/why-is-aardvark-therapeutics-stock-sinking-monday","article_id":"2616331734","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/02/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/50960206/why-is-aardvark-therapeutics-stock-sinking-monday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616331734","pubTimestamp":1772452920,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aardvark Therapeutics Inc.  shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.The decision comes as the company is conducting a comprehensive review of safety data.The company on Friday revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026. This pause was prompted by reversible cardiac observations at higher than target therapeutic doses found during routine safety monitoring in a healthy volunteer study.Aardvark’s CEO, Tien Lee, emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101. The company plans to continue collaborating closely with the FDA and the Prader-Willi Syndrome community while determining the next steps for its clinical program.“Assuming resolution of the cardiac safety event, Aardvark may be able to accelerate and streamline the","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics"},"translate_title":"为什么Aardvark Therapeutics股价周一下跌？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":1.5},"content_text":"Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\nThe decision comes as the company is conducting a comprehensive review of safety data.\nThe company on Friday revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026. This pause was prompted by reversible cardiac observations at higher than target therapeutic doses found during routine safety monitoring in a healthy volunteer study.\nAardvark’s CEO, Tien Lee, emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101. The company plans to continue collaborating closely with the FDA and the Prader-Willi Syndrome community while determining the next steps for its clinical program.\n“At this point, it is admittedly difficult to properly assess prospects of ARD-101 in Prader-Willi syndrome given the limited available information,” William Blair wrote in an investor note on Monday.\nAnalyst Andy T. Hsieh added that due to the severe disruption of the study pause, the ongoing Phase 3 HERO trial may not be fully completed. However, this outcome opens the possibility of the company electing to unblind the study early.\nHe highlighted that the management announced that greater than half of the target (90 patients) had been completed around mid-January, suggesting that unblinding the HERO study results could yield a sufficient sample size for investors to fully assess the risk/benefit profile of ARD-101.\n“Assuming resolution of the cardiac safety event, Aardvark may be able to accelerate and streamline the second pivotal study with increased confidence in its statistical and powering assumptions,” analyst Hsieh commented on Monday.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $29.78. Recent analyst moves include:\nAARD Price Action: Aardvark Therapeutics shares were down 55.88% at $5.51 during premarket trading on Monday. The stock is near its 52-week low of $4.88, according to Benzinga Pro data.\nPhoto via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616331734","isCrawlerRequest":true}